MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
Jiaofeng Huang,1,* Wenjuan Xue,2,* Mingfang Wang,1 Yinlian Wu,1 Medha Singh,3 Yueyong Zhu,1,4 Rahul Kumar,5 Su Lin1 1Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China;...
Guardado en:
Autores principales: | Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y, Kumar R, Lin S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d35b26b12fbc41f3b38e6c86900e9672 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease
por: Fan Y, et al.
Publicado: (2021) -
Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
por: Gwyneth Shook Ting Soon, et al.
Publicado: (2021) -
Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
por: Cao W, et al.
Publicado: (2021) -
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
por: Filip R, et al.
Publicado: (2018) -
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
por: Jorge Gutiérrez-Cuevas, et al.
Publicado: (2021)